Literature DB >> 7506856

Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy.

J A Eastham1, T G Wilson, C Russell, T E Ahlering, D G Skinner.   

Abstract

OBJECTIVE: Patients with high-stage nonseminomatous germ cell tumors treated with platinum-based chemotherapy who have residual radiographic evidence of disease and fail to normalize tumor markers present a difficult clinical dilemma. Some authors feel that these patients are not appropriate surgical candidates. Our practice has been to offer certain patients salvage surgery in an attempt for cure. This report is designed to review that experience and critically analyze the results.
METHOD: We report a series of 16 such patients with advanced-stage nonseminomatous germ cell tumors who had persistently elevated alpha fetoprotein and/or human chorionic gonadotropin. All underwent resection of all radiographically evident sites of residual disease following induction or salvage chemotherapy.
RESULTS: Ten patients had only retroperitoneal (RP) metastasis. Six patients had more than one site of residual disease--4 RP and lung, 2 RP and liver. There were no postoperative deaths. The mean postoperative stay was eleven days (range 7 to 36 days). Six patients (37%) are alive and free of disease at a mean of seventy-four months following surgery (range 20 to 145 months). Five had RP disease only. Ten patients died of disease at a mean of eight months postoperatively (range 5 to 21 months).
CONCLUSIONS: Patients with advanced nonseminomatous germ cell tumor who fail to normalize their serum tumor markers after adequate platinum-based chemotherapy should be considered for surgical resection of all radiographically evident residual disease. In select cases this practice offers the only viable chance for cure.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7506856     DOI: 10.1016/s0090-4295(94)80269-6

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  9 in total

1.  Surgical therapy for testicular cancer metastatic to the liver.

Authors:  Mary Maluccio; Lawrence H Einhorn; Robert J Goulet
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

Review 2.  Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer.

Authors:  Roy Mano; Renzo Di Natale; Joel Sheinfeld
Journal:  Urol Oncol       Date:  2018-11-13       Impact factor: 3.498

Review 3.  [Lymphadenectomy for testicular cancer. Diagnostic and prognostic significance as well as therapeutic benefit].

Authors:  S Krege; H Rübben
Journal:  Urologe A       Date:  2005-06       Impact factor: 0.639

4.  [The role of tumour markers in diagnosis and management of testicular germ cell tumours].

Authors:  S Krege; P Albers; A Heidenreich
Journal:  Urologe A       Date:  2011-03       Impact factor: 0.639

Review 5.  Serum tumor markers in the evaluation of male germ cell tumors.

Authors:  LaMont J Barlow; Gina M Badalato; James M McKiernan
Journal:  Nat Rev Urol       Date:  2010-11       Impact factor: 14.432

6.  Results of salvage retroperitoneal lymphadenectomy (RLA) in the treatment of patients with nonseminomatous germ cell tumours remaining marker positive after inductive chemotherapy.

Authors:  L Kisbenedek; I Bodrogi; P Szeldeli; M Baki; P Tenke; J Horti
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

7.  Management of poor-prognosis testicular germ cell tumors.

Authors:  Kiranpreet Khurana; Timothy D Gilligan; Andrew J Stephenson
Journal:  Indian J Urol       Date:  2010 Jan-Mar

8.  Microwave ablation (MWA) for the treatment of a solitary, chemorefractory testicular cancer liver metastasis.

Authors:  Elena G Violari; Elena N Petre; Darren R Feldman; Joseph P Erinjeri; Karen T Brown; Stephen B Solomon; Michael I D'Angelica; Constantinos T Sofocleous
Journal:  Cardiovasc Intervent Radiol       Date:  2014-06-18       Impact factor: 2.797

9.  Malignant mixed ovarian germ cell tumor composed of immature teratoma, yolk sac tumor and embryonal carcinoma harboring an EGFR mutation: a case report.

Authors:  Yao Wang; Jia-Xin Yang; Mei Yu; Dong-Yan Cao; Keng Shen
Journal:  Onco Targets Ther       Date:  2018-10-12       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.